PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Receives Consensus Rating of “Moderate Buy” from Brokerages

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $59.7778.

PRCT has been the topic of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Wednesday, October 8th. TD Cowen dropped their target price on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Wall Street Zen downgraded shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Truist Financial lowered their price target on shares of PROCEPT BioRobotics from $64.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, October 15th. Finally, Oppenheimer raised shares of PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price objective on the stock in a research note on Tuesday, September 2nd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alliancebernstein L.P. raised its stake in PROCEPT BioRobotics by 58.6% during the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after buying an additional 1,262,928 shares during the last quarter. Chicago Capital LLC increased its holdings in shares of PROCEPT BioRobotics by 175.7% during the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock valued at $55,992,000 after acquiring an additional 999,873 shares in the last quarter. Westfield Capital Management Co. LP raised its position in shares of PROCEPT BioRobotics by 113.5% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,598,349 shares of the company’s stock worth $92,065,000 after purchasing an additional 849,792 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in PROCEPT BioRobotics by 229.7% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,128,288 shares of the company’s stock worth $40,269,000 after purchasing an additional 786,094 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its stake in PROCEPT BioRobotics by 105.2% in the 3rd quarter. Mackenzie Financial Corp now owns 1,454,434 shares of the company’s stock worth $51,909,000 after purchasing an additional 745,778 shares in the last quarter. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $29.86 on Monday. PROCEPT BioRobotics has a 1 year low of $27.80 and a 1 year high of $100.89. The stock has a market capitalization of $1.67 billion, a P/E ratio of -19.52 and a beta of 0.99. The company’s 50-day moving average is $34.18 and its 200 day moving average is $45.86. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.03. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The business had revenue of $83.33 million for the quarter, compared to analysts’ expectations of $80.78 million. During the same period in the previous year, the firm posted ($0.40) EPS. The business’s revenue was up 42.6% on a year-over-year basis. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts expect that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).